Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.

Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W

Medicine1 May 2021Cited by 6 (Europe PMC)

PMID34011034PMCIDPMC8137107DOI10.1097/md.0000000000025749PepBankPUB-34011034

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In patients with solitary HBV-related HCC after curative resection, the immunological response improved in the Tα1 group compared with the control group.
In plain wordsAfter liver cancer surgery, immune response measures improved more with thymosin alpha‑1 than without it.
Peptide
Thymosin alpha-1
Outcome
IncreaseImmunological response
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Immunological response improved in the Tα1 group compared with the control group (P < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103401
02HumanObservational studyEfficacy outcome
In patients with solitary HBV-related HCC after curative resection, the virologic response was similar between the Tα1 and control groups after 24 months.
In plain wordsAfter liver cancer surgery, the virus response at 24 months was similar with and without thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
No significant changeVirologic response at 24 months
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
but the virologic response was similar between 2 groups after 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103402
03HumanObservational studyEfficacy outcome
Patients with Tα1 therapy had better recurrence-free survival than control patients, before and after propensity matching.
In plain wordsAfter liver cancer surgery, patients given thymosin alpha‑1 stayed free of recurrence longer than those not given it.
Peptide
Thymosin alpha-1
Outcome
IncreaseRecurrence-free survival
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Patients with Tα1 therapy had better RFS and OS before (P = .018 and P < .001) and after (P = .006 and P < .001) propensity matching.
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103403
04HumanObservational studyEfficacy outcome
Patients with Tα1 therapy had better overall survival than control patients, before and after propensity matching.
In plain wordsAfter liver cancer surgery, patients given thymosin alpha‑1 lived longer than those not given it.
Peptide
Thymosin alpha-1
Outcome
IncreaseOverall survival
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Mortality · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Patients with Tα1 therapy had better RFS and OS before (P = .018 and P < .001) and after (P = .006 and P < .001) propensity matching.
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103404
05HumanObservational studyEfficacy outcome
In multivariate analysis, Tα1 therapy was an independent prognostic factor for overall survival (HR 0.308, 95% CI 0.175-0.541).
In plain wordsAfter adjusting for other factors, thymosin alpha‑1 was linked to a lower risk of death after liver cancer surgery.
Peptide
Thymosin alpha-1
Outcome
DecreaseOverall survival, multivariate hazard ratio
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Mortality · Cancer
Studied dose
Dose not stated
Measurements
HR
0.308 ratio
overall survival, Tα1 therapy
Source sentences
Summary
Multivariate analysis revealed that Tα1 therapy was an independent prognostic factor for both OS (P < .001, HR = 0.308, 95% CI: 0.175-0.541) and RFS (P < .001, HR = 0.381, 95% CI: 0.229-0.633)
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103405
06HumanObservational studyEfficacy outcome
In multivariate analysis, Tα1 therapy was an independent prognostic factor for recurrence-free survival (HR 0.381, 95% CI 0.229-0.633).
In plain wordsAfter adjusting for other factors, thymosin alpha‑1 was linked to a lower risk of cancer recurrence after liver cancer surgery.
Peptide
Thymosin alpha-1
Outcome
DecreaseRecurrence-free survival, multivariate hazard ratio
Study
n = 468
Comparator
Control group without Tα1
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
HR
0.381 ratio
recurrence-free survival, Tα1 therapy
Source sentences
Summary
Multivariate analysis revealed that Tα1 therapy was an independent prognostic factor for both OS (P < .001, HR = 0.308, 95% CI: 0.175-0.541) and RFS (P < .001, HR = 0.381, 95% CI: 0.229-0.633)
1 context sentence(design, population, supporting numbers)
Summary · context
Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection.Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed.
Report a problemFND-3401103406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.